Details for Patent: 9,333,310

Which drugs does patent 9,333,310 protect, and when does it expire?

Patent 9,333,310 protects INCRUSE ELLIPTA, ANORO ELLIPTA, ARNUITY ELLIPTA, BREO ELLIPTA, and TRELEGY ELLIPTA, and is included in five NDAs.

Protection for ANORO ELLIPTA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has nineteen patent family members in seventeen countries.

Summary for Patent: 9,333,310

Title:	Medicament dispenser
Abstract:	A sheet driver for use in a medicament dispenser with blister pockets includes: (a) a base, extending from the base, (b) a shaft defining a rotational axis; at the base, (c) a drive surface for receipt of drive to rotate the base about the rotational axis; about the shaft, (d) a torsion spring defining first and second spring legs; mounting about the shaft and the torsion spring for rotation about the rotational axis, and (e) a hub defining a hub surface for receipt of a sheet of the medicament carrier, the hub surface being adapted to provide an initial effective winding surface which provides uniform indexing of the medicament carrier.
Inventor(s):	Jones; Christopher John (Warwick, GB), May; James John (Warwick, GB), Lintell; Daniel Thomas De Sausmarez (Ware, GB), Palmer; Mark Gregory (Ware, GB), Tansley; Robert William (Bidford on Avon, GB)
Assignee:	Glaxo Group Limited (Brentford, Middlesex, GB)
Application Number:	13/483,168
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 9,333,310

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Glaxo Grp England	INCRUSE ELLIPTA	umeclidinium bromide	POWDER;INHALATION	205382-001	Apr 30, 2014		RX	Yes	Yes			Y
Glaxosmithkline	ANORO ELLIPTA	umeclidinium bromide; vilanterol trifenatate	POWDER;INHALATION	203975-001	Dec 18, 2013		RX	Yes	Yes					Y
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-003	May 17, 2018		RX	Yes	Yes					Y
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-001	Aug 20, 2014		RX	Yes	Yes					Y
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-002	Aug 20, 2014		RX	Yes	Yes					Y
Glaxo Grp Ltd	BREO ELLIPTA	fluticasone furoate; vilanterol trifenatate	POWDER;INHALATION	204275-003	May 12, 2023		RX	Yes	No					Y

Foreign Priority and PCT Information for Patent: 9,333,310

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0418278.8	Aug 16, 2004

International Family Members for US Patent 9,333,310

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005274296
Brazil	PI0514346
Canada	2577248
China	100528256
China	101084030
Cyprus	1117205